This unique series of four live, one-day meetings will provide expert reviews of the most meaningful and practice-changing data in the field of hematology presented at ASH and other major society meetings held throughout 2011. In addition to didactic lectures, the format of the meeting also includes interactive “The Smartest Oncologist/Hematologist Quizzes.”

Hagop Kantarjian, MD (Series Chair) The University of Texas M. D. Anderson Cancer Center Houston, Texas Kenneth C. Anderson, MD Dana-Farber Cancer Institute Boston, Massachusetts James Armitage, MD University of Nebraska Medical Center Omaha, Nebraska Jorge Cortes, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Eric J. Feldman, MD Weill Cornell Medical College New York, New York Guillermo Garcia-Manero, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Irene Ghobrial, MD Dana-Farber Cancer Institute Boston, Massachusetts Elias Jabbour, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas Sagar Lonial, MD Emory University School of Medicine Atlanta, Georgia Reshma Mahtani, DO  Sylvester Comprehensive Cancer Center Deerfield Beach, Florida Ruben Mesa, MD, FACP  Mayo Clinic Scottsdale, Arizona

Stephan Moll, MD UNC School of Medicine Chapel Hill, North Carolina Susan O'Brien, MD The University of Texas M. D. Anderson Cancer Center Houston, Texas S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota Charles Schiffer, MD Karmanos Cancer Institute Detroit, Michigan Jorge Spinolo, MD, FACP Georgia Cancer Specialists Atlanta, GA Richard Stone, MD Dana-Farber Cancer Institute Boston, Massachusetts David Straus, MD Memorial Sloan-Kettering Cancer Center New York, New York Ayalew Tefferi, MD Mayo Clinic Rochester, Minnesota Srdan Verstovsek, MD, PhD The University of Texas M. D. Anderson Cancer Center Houston, Texas Julie Vose, MD University of Nebraska Medical Center Omaha, Nebraska Meir Wetzler, MD, FACP Roswell Park Cancer Institute Buffalo, New York

Physicians / Mid-Level Providers / Nurses

• Physician preregistration: $75.00
• Physician onsite registration: $100.00
• Mid-Level Provider / Nurse preregistration: $35.00*
• Mid-Level Provider / Nurse onsite registration: $50.00*

*Supporting documentation of eligibility may be required.



Preregistration will close on the following days for each meeting:

 

• Atlanta – January 18, 2012
• New York – January 25, 2012
• Houston – February 8, 2012
• Hollywood – February 22, 2012

 

After preregistration closes, the price will increase to the onsite rate. Attendees may still register online or onsite the morning of the meeting.



Residents/Fellows
Residents/Fellows are eligible for complimentary registration. Please contact hemehighlights@primeoncology.org for more information.


ONS Members
ONS members are eligible for discounted registration rates. Please email hemehighlights@primeoncology.org with the name of your ONS chapter for more information.


The registration fee includes all program materials, continental breakfast, lunch, and refreshment breaks. prIME Oncology does not accept liability for travel, accommodations, or any other costs incurred by registrants.



Cancellation/Substitutions Policy
The registration fee is nonrefundable. Substitutions will be accepted up to one week prior to the meeting date with written notice.

Who Should Attend
This educational activity is intended for hematologists, oncologists, oncology specialist nurses, and other allied healthcare professionals interested in the management of hematologic malignancies and coagulation disorders.


Statement of Need 
As the rate at which clinical data are released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists, and other physicians involved in the management of hematologic malignancies do not attend major society meetings. Likewise, those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists and hematologists. In addition, the data presented at large clinical conferences are typically not framed in the context of the clinical practice of community oncologists/hematologists. prIME Oncology presents “Hematologic Malignancies Demystified: The Series—A Critical Appraisal of Data from 2011,” to review, summarize, and interpret the most clinically significant data released in 2011 in an effort to meet this need.


Educational Objectives
Upon completion of this educational activity, participants should be better able to:

• Discuss the most recent clinical trial data regarding treatment of patients with hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms
• Describe emerging therapies and novel treatment strategies for patients with hematologic malignancies and evaluate the practical utility of novel agents based on data from recent clinical studies
• Examine the use of molecular markers and patient characteristics to guide the therapeutic decision-making process in patients with hematologic malignancies
• Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologist and identify appropriate management options based on emerging data
• Describe the role of coagulation medicine in patients with cancer